Master Hypothesis Table: Likelihood and Therapeutic Potential
Table Master Hypothesis Table: Likelihood and Therapeutic Potential provides a comprehensive overview of all hypotheses presented in this chapter, ranked by evidence strength and therapeutic potential. This serves as a roadmap for both researchers prioritizing investigation directions and clinicians considering experimental interventions.
#landscape[
| Hypothesis | Evidence Level | Therapeutic Potential | Benefit: Mild | Benefit: Severe | Explains Key Features | Nearest-Term Action |
|---|---|---|---|---|---|---|
| CPET-Derived Hypotheses (Objective Functional Data) | ||||||
| Autonomic-mitochondrial feedback loop | Moderate | High | High | Moderate | PEM, recovery time, autonomic symptoms | Trial: tyrosine + BH4 + antioxidants |
| Mitochondrial turnover rate limitation | Moderate–High | High | Moderate–High | Moderate | 13-day recovery, cumulative decline, GET failure | Urolithin A + NAD+ precursor trial |
| Exercise metabolomics-guided therapy | Moderate | Very High | High | Low | Individual variation, treatment heterogeneity | Post-CPET metabolomics study |
| Circadian recovery gating | Low–Moderate | Moderate | Moderate | Moderate | Sleep dysfunction, non-restorative rest | Chronotherapy pilot study |
| Vagal stimulation for recovery | Low–Moderate | Moderate | Moderate | Low–Moderate | Autonomic dysfunction, inflammation persistence | Post-exertion VNS trial |
| Core Mechanistic Hypotheses | ||||||
| Metabolic “safe mode” lock | Moderate | High | Low–Moderate | Moderate–High | PEM, chronicity, resistance to rehabilitation | Hypothalamic modulation interventions |
| Glymphatic clearance failure | Low–Moderate | Moderate | Moderate | Moderate–High | Brain fog, non-restorative sleep, orthostatic symptoms | CSF flow imaging; craniocervical assessment |
| Tryptophan/kynurenine trap | Moderate | Moderate–High | Moderate | Moderate | Cognitive symptoms, depression, immune activation | IDO inhibition trials |
| Vagal afferent danger signal loop | Low–Moderate | Moderate–High | Moderate | High | Rapid symptom onset, gut-brain connection, PEM | Vagal modulation; gut interventions |
| Purinergic signaling dysregulation | Low–Moderate | Moderate | Moderate | Moderate | Immune dysfunction, pain, fatigue, inflammation | P2X/P2Y receptor modulators |
| Redox compartment collapse | Moderate | Moderate | Moderate | Low–Moderate | Oxidative stress, chemical sensitivities | Glutathione/NAC optimization |
| Metabolic memory/epigenetic lock | Moderate | Low–Moderate | Low | Low–Moderate | Chronicity, treatment resistance | Epigenetic modifiers (exploratory) |
| Circadian-metabolic desynchronization | Moderate | Moderate | Moderate | Low–Moderate | Sleep issues, energy fluctuations | Circadian stabilization protocols |
| Autoimmune/Immune Hypotheses | ||||||
| GPCR autoantibody-driven dysfunction | Moderate–High | Very High | High | Moderate–High | POTS, autonomic symptoms, 60% daratumumab response | Autoantibody testing; immunoadsorption; daratumumab |
| Plasma cell sanctuary hypothesis | Moderate | Very High | High | High | Rituximab failure vs daratumumab success, chronicity | Anti-CD38 therapy; combined IA + daratumumab |
| Autoantibody-monocyte activation cascade | Low–Moderate | Moderate–High | Moderate | Moderate | Inflammatory cytokines, MIP-1\(\delta\), PDGF-BB elevation | Monocyte-targeted therapy; autoantibody removal |
| Ion channel autoimmunity | Low–Moderate | Moderate–High | Moderate–High | Moderate | Autonomic symptoms, POTS, cognitive issues | Autoantibody screening; immunoadsorption |
| TRPM3 channelopathy | Moderate–High | High | High | Moderate–High | NK cell dysfunction, impaired immune cell calcium signaling | TRPM3 functional testing; calcium signaling studies; pregnenolone trial (speculative) |
| Endothelial trained immunity | Low | Moderate–High | Moderate | Moderate | Multi-system symptoms, vascular dysfunction, PEM | Endothelial epigenetic profiling |
| Receptor internalization (not blockade) | Low–Moderate | Moderate–High | Moderate | Moderate | Lag between Ab removal and improvement; receptor density changes | Receptor density assays on patient lymphocytes |
| Functional vs. binding assay discrepancy | Moderate | Very High | High | High | Failed replications; heterogeneous treatment response | Develop functional autoantibody assays |
| Viral/Cellular Hypotheses | ||||||
| EBV-B cell CNS infiltration | Low–Moderate | High | Moderate | Moderate–High | Post-EBV onset; neuroinflammation; brain fog | CSF B cell analysis; LMP1 profiling |
| EBV-GPCR molecular mimicry | Low | High | Moderate–High | Moderate–High | EBV trigger specificity; persistent autoantibodies | Computational homology; cross-reactivity testing |
| Endogenous retrovirus reactivation | Very Low | Low | Low | Low | Post-viral onset, immune activation, chronicity | HERVs expression profiling |
| Cellular quorum sensing dysfunction | Very Low | Low | Low–Moderate | Low | Systemic coordination loss, multi-system involvement | Basic research needed |
| Metabolic Compartmentalization Hypotheses | ||||||
| Lactate compartmentalization disorder | Low | Moderate | Low–Moderate | Low–Moderate | Exercise intolerance, muscle symptoms, brain lactate | MCT function studies; dietary ketones |
| Ferroptosis susceptibility | Low | Low–Moderate | Low–Moderate | Low | Oxidative stress, lipid peroxidation, tissue damage | Ferroptosis inhibitors (research) |
| Integrated/Multi-System Hypotheses | ||||||
| Selective energy dysfunction | Moderate | High | Moderate–High | Moderate–High | Preserved autonomous functions (hair, nails), impaired CNS-dependent processes; demand-response failure | Hair follicle mito assay; CSF lactate; CNS-targeted delivery (Section Selective Energy Dysfunction Hypothesis) |
| Multi-lock integrated trap | High conceptual | Very High | Variable | Variable | Heterogeneity, treatment resistance, chronicity | Multi-target interventions |
| Cycle Dynamics Hypotheses | ||||||
| Vicious cycle network coupling | Moderate | Very High | High | High | Treatment resistance, heterogeneity, why single interventions fail | Multi-target combination trials (CoQ10 + LDN); biomarker-guided selection |
| Critical transition bifurcation | Low–Moderate | High | High | Moderate | Sudden deteriorations, non-linear progression, “tipping points” | Longitudinal monitoring for warning signals (increased symptom variance) |
| Cycle-predominant subgroups | Moderate | High | High | High | Treatment heterogeneity, why same treatment works for some | Comprehensive cycle diagnostic battery; targeted interventions |
| Crash dose-response with threshold | Moderate–High | Very High | Very High | Very High | Why small overexertion can be catastrophic, cumulative harm | Individual VT measurement; strict envelope pacing |
| Time-dependent reversibility decay | Low–Moderate | High | High | Moderate | Why early intervention crucial, chronic treatment resistance | Aggressive early treatment; realistic expectation setting |
| Cycle recruitment cascade | Low–Moderate | Moderate–High | Very High | Low–Moderate | Disease progression, why mild becomes severe without intervention | Early pacing to prevent cascade; monitor for new cycle activation |
| High-Risk/Counterintuitive Hypotheses | ||||||
| Metabolic preconditioning (hormesis) | Very Low | Low (High Risk) | Unknown | Contraindicated | Adaptation failure? | NOT RECOMMENDED clinically |
| Blood flow restriction training | Low | Low–Moderate | Low–Moderate | Contraindicated | Oxygen delivery dysfunction | Research only; high risk |
:::
1 How to Use This Table
1.1 For Researchers
High-priority investigations (Moderate-High evidence, testable):
- TRPM3 channelopathy: Replication in additional cohorts; characterization of dysfunction mechanism (hypo- vs hyperfunction); correlation with symptom severity
- Mitochondrial turnover limitation: Urolithin A intervention with repeat two-day CPET
- Autonomic-mitochondrial loop: Multi-target combination trial
- Exercise metabolomics: Post-CPET metabolomic profiling to identify subgroups
- Ion channel autoimmunity: Comprehensive autoantibody screening (including anti-TRPM3)
Medium-priority investigations (plausible mechanisms, need preliminary data):
- Glymphatic function: Imaging studies assessing CSF flow dynamics
- Tryptophan trap: IDO inhibitor safety/efficacy trials
- Vagal interventions: VNS for post-exertional recovery
- Circadian optimization: Chronotherapy protocols
Basic research needed (very low evidence, high theoretical interest):
- Cellular quorum sensing mechanisms
- Endogenous retrovirus expression patterns
- Ferroptosis markers and susceptibility
1.2 For Clinicians
Relatively safe to trial (assuming medical supervision and appropriate patient selection):
- Autonomic-mitochondrial support (supplements, generally recognized as safe)
- Mitochondrial turnover acceleration (urolithin A, NAD+ precursors have human safety data)
- Chronotherapy/circadian stabilization (behavioral, very low risk)
- Vagal stimulation (non-invasive, established safety profile)
- Tryptophan metabolism support (within normal supplement ranges)
Requires specialist supervision:
- Ion channel autoantibody testing and immunoadsorption
- IDO inhibition (investigational)
- Epigenetic modifiers
Not recommended outside research protocols:
- Metabolic preconditioning/hormesis approaches (high risk of PEM)
- Blood flow restriction training (could worsen oxygen delivery dysfunction)
- Endogenous retrovirus interventions (purely theoretical)
1.3 For Patients
Understanding evidence levels:
- Very Low: Purely theoretical speculation; interesting for research but no evidence
- Low: Mechanism makes sense based on other diseases; no ME/CFS-specific data
- Low-Moderate: Some indirect evidence in ME/CFS; plausible but unproven
- Moderate: Multiple ME/CFS studies support mechanism; direct intervention untested
- Moderate-High: Strong mechanistic support; similar interventions show promise
- High: Direct evidence from ME/CFS trials (rare in this chapter, as these are speculative hypotheses)
Severity-specific guidance:
- Mild-moderate patients: May benefit from metabolomics-guided approaches, autonomic support, circadian optimization
- Severe patients: Prioritize hypotheses addressing core metabolic function (safe mode, mitochondrial turnover, glymphatic clearance); avoid any interventions requiring exertion
- All severities: Multi-lock hypothesis suggests combinations may work better than single interventions
2 Qualification and Caveats
CautionWarning: Speculative Content
ALL hypotheses in this chapter are speculative to varying degrees. The evidence levels indicate relative plausibility and existing support, but even “Moderate-High” evidence hypotheses remain unproven. Therapeutic approaches derived from these hypotheses should be considered experimental and discussed with knowledgeable physicians. Patient self-experimentation carries risks, especially for severe patients where any metabolic perturbation might trigger crashes.